These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 38663803)

  • 1. Growth differentiation factor-15 and metabolic features in chronic heart failure: Insights from the SUPPORT Trial -GDF15 across the BMI spectrum.
    Teramoto K; Nochioka K; Sakata Y; Kato ET; Nishimura K; Shimokawa H; Yasuda S;
    Int J Cardiol; 2024 Jul; 407():132093. PubMed ID: 38663803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic significance of growth differentiation factor-15 across age in chronic heart failure.
    Teramoto K; Nochioka K; Sakata Y; Nishimura K; Shimokawa H; Yasuda S;
    ESC Heart Fail; 2024 Jun; 11(3):1666-1676. PubMed ID: 38426613
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The association between serum growth differentiation factor 15 levels and lower extremity atherosclerotic disease is independent of body mass index in type 2 diabetes.
    He X; Su J; Ma X; Lu W; Zhu W; Wang Y; Bao Y; Zhou J
    Cardiovasc Diabetol; 2020 Mar; 19(1):40. PubMed ID: 32222153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Body mass index and outcomes of cardiac resynchronization with implantable cardioverter-defibrillator therapy in older patients with heart failure.
    Echouffo-Tcheugui JB; Masoudi FA; Bao H; Curtis JP; Heidenreich PA; Fonarow GC
    Eur J Heart Fail; 2019 Sep; 21(9):1093-1102. PubMed ID: 31359595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Growth differentiation factor 15 in heart failure with preserved vs. reduced ejection fraction.
    Chan MM; Santhanakrishnan R; Chong JP; Chen Z; Tai BC; Liew OW; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong RC; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2016 Jan; 18(1):81-8. PubMed ID: 26497848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Growth Differentiation Factor 15 and Clinical Outcomes in Japanese Patients With Heart Failure.
    Otaki Y; Shimizu M; Watanabe T; Tachibana S; Sato J; Kobayashi Y; Aono T; Kato S; Tamura H; Nishiyama S; Arimoto T; Takahashi H; Watanabe M
    Circ J; 2023 Jul; 87(8):1120-1129. PubMed ID: 36948614
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth differentiation factor 15, ST2, high-sensitivity troponin T, and N-terminal pro brain natriuretic peptide in heart failure with preserved vs. reduced ejection fraction.
    Santhanakrishnan R; Chong JP; Ng TP; Ling LH; Sim D; Leong KT; Yeo PS; Ong HY; Jaufeerally F; Wong R; Chai P; Low AF; Richards AM; Lam CS
    Eur J Heart Fail; 2012 Dec; 14(12):1338-47. PubMed ID: 22869458
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Growth differentiation factor 15 is related to anemia and iron metabolism in heart allograft recipients and patients with chronic heart failure.
    Przybyłowski P; Wasilewski G; Bachorzewska-Gajewska H; Golabek K; Dobrzycki S; Małyszko J
    Transplant Proc; 2014 Oct; 46(8):2852-5. PubMed ID: 25380934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between body mass index and prognosis of patients hospitalized with heart failure.
    Seko Y; Kato T; Morimoto T; Yaku H; Inuzuka Y; Tamaki Y; Ozasa N; Shiba M; Yamamoto E; Yoshikawa Y; Yamashita Y; Kitai T; Taniguchi R; Iguchi M; Nagao K; Kawai T; Komasa A; Nishikawa R; Kawase Y; Morinaga T; Toyofuku M; Furukawa Y; Ando K; Kadota K; Sato Y; Kuwahara K; Kimura T
    Sci Rep; 2020 Oct; 10(1):16663. PubMed ID: 33028856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of obesity with cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease: Insights from TECOS.
    Pagidipati NJ; Zheng Y; Green JB; McGuire DK; Mentz RJ; Shah S; Aschner P; Delibasi T; Rodbard HW; Westerhout CM; Holman RR; Peterson ED;
    Am Heart J; 2020 Jan; 219():47-57. PubMed ID: 31707324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma GDF15 levels are similar between subjects after bariatric surgery and matched controls and are unaffected by meals.
    Martinussen C; Svane MS; Bojsen-Møller KN; Jensen CZ; Kristiansen VB; Bookout AL; Jørgensen SB; Holst JJ; Wewer Albrechtsen NJ; Madsbad S; Kuhre RE
    Am J Physiol Endocrinol Metab; 2021 Oct; 321(4):E443-E452. PubMed ID: 34370594
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Circulating total and H-specific GDF15 levels are elevated in subjects with MASLD but not in hyperlipidemic but otherwise metabolically healthy subjects with obesity.
    Boutari C; Stefanakis K; Simati S; Guatibonza-García V; Valenzuela-Vallejo L; Anastasiou IA; Connelly MA; Kokkinos A; Mantzoros CS
    Cardiovasc Diabetol; 2024 May; 23(1):174. PubMed ID: 38762719
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Body mass index and cancer incidence:a prospective cohort study in northern China].
    Guo L; Li N; Wang G; Su K; Li F; Yang L; Ren J; Chang S; Chen S; Wu S; He J; Dai M
    Zhonghua Liu Xing Bing Xue Za Zhi; 2014 Mar; 35(3):231-6. PubMed ID: 24831616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased heart failure risk in normal-weight people with metabolic syndrome compared with metabolically healthy obese individuals.
    Voulgari C; Tentolouris N; Dilaveris P; Tousoulis D; Katsilambros N; Stefanadis C
    J Am Coll Cardiol; 2011 Sep; 58(13):1343-50. PubMed ID: 21920263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased Growth Differentiation Factor 15 in Patients with Hypoleptinemia-Associated Lipodystrophy.
    Kralisch S; Hoffmann A; Estrada-Kunz J; Stumvoll M; Fasshauer M; Tönjes A; Miehle K
    Int J Mol Sci; 2020 Sep; 21(19):. PubMed ID: 33003626
    [No Abstract]   [Full Text] [Related]  

  • 16. The obesity paradox: body mass index and outcomes in patients with heart failure.
    Curtis JP; Selter JG; Wang Y; Rathore SS; Jovin IS; Jadbabaie F; Kosiborod M; Portnay EL; Sokol SI; Bader F; Krumholz HM
    Arch Intern Med; 2005 Jan; 165(1):55-61. PubMed ID: 15642875
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced levels of vasopressin, an independent mechanism in the obesity paradox in patients with chronic heart failure: Insights from the DAMOCLES study.
    Gavaldà-Manso M; Jimenez-Marrero S; Cainzos-Achirica M; Garay A; Enjuanes C; Yun S; Diez C; Gonzalez-Costello J; Tajes M; Farre N; Duran X; Comin-Colet J
    Int J Cardiol; 2019 Feb; 276():171-176. PubMed ID: 30409739
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum GDF15, a Promising Biomarker in Obese Patients Undergoing Heart Surgery.
    Sarkar S; Legere S; Haidl I; Marshall J; MacLeod JB; Aguiar C; Lutchmedial S; Hassan A; Brunt KR; Kienesberger P; Pulinilkunnil T; Légaré JF
    Front Cardiovasc Med; 2020; 7():103. PubMed ID: 32671100
    [No Abstract]   [Full Text] [Related]  

  • 19. Circulating concentrations of growth-differentiation factor 15 in apparently healthy elderly individuals and patients with chronic heart failure as assessed by a new immunoradiometric sandwich assay.
    Kempf T; Horn-Wichmann R; Brabant G; Peter T; Allhoff T; Klein G; Drexler H; Johnston N; Wallentin L; Wollert KC
    Clin Chem; 2007 Feb; 53(2):284-91. PubMed ID: 17185363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between underweight and risk of heart failure in diabetes patients.
    Yoo TK; Han KD; Rhee EJ; Lee WY
    J Cachexia Sarcopenia Muscle; 2024 Apr; 15(2):671-680. PubMed ID: 38221512
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.